Intravenous immunoglobulin in the Guillain-Barre syndrome

BMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7069.1399c (Published 30 November 1996) Cite this as: BMJ 1996;313:1399

May cause severe adverse skin reactions

  1. H H M Hamdalla,
  2. C H Hawkes,
  3. E G Spokes,
  4. J M Bamford,
  5. P J Goulding
  1. Registrar Locum Consultant Department of Neurology, General Infirmary, Leeds LS1 3EX
  2. Consultant Consultant Department of Neurology, St James's University Hospital, Leeds LS1 3EX

    EDITOR,—R A C Hughes's editorial on the use of intravenous immunoglobulin in the Guillain-Barre syndrome concludes that this treatment is beneficial and is easier than plasma exchange to administer.1 We agree with this but wish to draw attention to potentially severe adverse skin reactions to the treatment. We report here on four patients who each received a five day course of intravenous immunoglobulin at the standard dose of 0.4 g/kg/day. Three were given Sandoglobulin, while the other received intravenous immunoglobulin prepared by the …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription